The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis

Save

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials.

Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS)

Save

Despite the increasing scientific knowledge on axSpAs, a substantial gap still remains. Delay in diagnosis continues to pose a threat in the early identification of patients and those already on treatment may deal with additional issues such as work productivity or quality of life.

Risankizumab for Active Psoriatic Arthritis

Save

The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.

Opening Day Report

Save

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Towards better assessment and management of multimorbidity

Save

Appropriate assessment and management of comorbidities and multimorbidity in patients with RA is vital for overall health and well-being of the patient, as well as to encourage treatment adherence, and address social, psychological and quality of life factors. 

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

Save

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Novel treatment options for Giant Cell Arteritis

Save

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

Pre-clinical RA: starting off the wrong foot

Save

Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.

Outcomes of COVID-19 in Patients with Rheumatoid Arthritis

Save

Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past decade, an armamentarium of biologic and targeted therapies has led to better control of disease activity in patients with rheumatoid arthritis. Whether these patients, especially those receiving newer biological and targeted therapies such as JAK inhibitors, are at an increased risk of severe COVID-19 outcomes remains uncertain. 

RheumNow Podcast – ACR Convergence Begins (11.5.2021)

Save

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.

Polyautoimmunity: axSpA and Familial Mediterranean Fever

Save

Mysteries behind polyautoimmunity have confounded rheumatologists for decades. One such association, the co-existence of Familial Mediterranean Fever (FMF) and axial spondyloarthritis (axSpA), remains rare. In fact, we believe the rate to be between 0.5% and 7.5%.

Prolonging the Controversy of Hydroxychloroquine

Save

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19.